China Pharma Holdings (CPHI) Receivables (2010 - 2026)

China Pharma Holdings (CPHI) has reported Receivables for 17 consecutive years, with $262476.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables fell 98.12% year-over-year to $262476.0; the trailing twelve-month figure through Jun 2026 stood at $262476.0 (down 98.12% YoY), and the FY2025 full-year result was $303696.0, down 97.81% from the prior year.
• Receivables fell to $262476.0 in Q2 2026 per CPHI's latest filing, from $267353.0 in the prior quarter.
• Across five years, Receivables topped out at $14.4 million in Q4 2023 and bottomed at $107254.0 in Q1 2023.
• Historically, Receivables has averaged $5.8 million across 5 years, with a median of $1.2 million in 2022.
• The sharpest annual moves came in 2024 and 2026: Receivables jumped 13093.89% in 2024, then tumbled 98.12% in 2026.
• Over 5 years, Receivables stood at $450670.0 in 2022, then soared by 3106.0% to $14.4 million in 2023, then retreated by 4.14% to $13.8 million in 2024, then tumbled by 97.81% to $303696.0 in 2025, then declined by 13.57% to $262476.0 in 2026.
• According to Business Quant data, Receivables over the past three periods registered $262476.0, $267353.0, and $303696.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.